Abstract 931P
Background
Currently, there is a paucity of validated deep learning methodologies for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma (NPC), both domestically and internationally. Furthermore, advanced techniques such as 2.5D feature extraction and Transformer model establishment remain underexplored in this context.
Methods
MRI images from locally advanced NPC patients diagnosed at two centers between July 2020 and June 2023 were retrospectively collected. Three state-of-the-art (SOTA) models (SegResNet, Unet, and UnetR models) were employed for automatic segmentation of all regions of interest (ROIs), thus generating an automatic segmentation model. Leveraging 2.5D deep learning techniques, tumor image features were extracted and integrated into a transfer learning framework. Subsequently, a Transformer-based model was designed, integrating all individual patient features. Three models were established: a clinical model, a Transformer model, and a fusion model. The predictive performance of these models was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).
Results
Among the three models, the Transformer model demonstrated superior predictive performance in both the testing (AUC = 0.957) and validation cohorts (AUC = 0.893) compared to the clinical model. Moreover, the fusion model generally matched or surpassed the performance of the Transformer model, particularly in the testing cohort with an AUC of 0.874, indicating that the integration of clinical data with advanced machine learning models can enhance predictive capability.
Conclusions
The fusion model, which combines machine learning with clinical factors, exhibits promising efficacy in predicting short-term outcomes in locally advanced NPC patients following synchronous chemoradiotherapy.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1036P - Large-scale cellular profiling of 1283 cancer patients reveals a NK cell-mediated immunosuppressive tumor microenvironment in immunotherapy resistance
Presenter: Yumo Xie
Session: Poster session 03
1037P - Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484
Presenter: Hakimeh Ebrahimi-Nik
Session: Poster session 03
Resources:
Abstract
1038P - Interactions of immune checkpoint blockade and regulatory T cells
Presenter: Dylan Muldoon
Session: Poster session 03
1039P - Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy
Presenter: Eduard Teixidor Vilà
Session: Poster session 03
1040P - Chemotherapy remodels the tumor immune microenvironment to increase the pCR rate of anti-PD-1 neoadjuvant therapy in MSS/pMMR locally advanced colon cancer: A prospective clinical trial and translational study
Presenter: Changjing Cai
Session: Poster session 03
Resources:
Abstract
1041P - ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1
Presenter: Pierre MARSCHALL
Session: Poster session 03
1042P - Rapid, single-step monitoring of circulating monoclonal antibodies using an aptamer-based electrochemical sensing platform
Presenter: Raffaella Ergasti
Session: Poster session 03
1043P - Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations
Presenter: Kirsty Crame
Session: Poster session 03
1044P - UniTope & TraCR: Universal tagging and tracking system for TCR-T cells integrated directly in the TCR constant region
Presenter: Kirsty Crame
Session: Poster session 03
1045P - The association of human leukocyte antigen variants in immune-related toxicity and efficacy in Chinese lung cancer patients treated with immune checkpoint inhibitors
Presenter: Yongchang Zhang
Session: Poster session 03